drugset / Trial / NCT00002580

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

NCT00002580

Phase 3 Completed 1000 enrolled Scottish Cancer Therapy Network
RandomizedTreatment

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with that of ovarian ablation, and/or combination chemotherapy in treating premenopausal women with stage I, stage II, or stage IIIA breast cancer.

Timeline

Start
1993-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Goserelin Other / unclassified Subcutaneous
Subject Leuprolide Other / unclassified Subcutaneous
Subject Methotrexate Small molecule Intravenous
Subject Tamoxifen Small molecule Oral
Subject fluorouracil Small molecule Intravenous

Indications